Publikationsdatenbank

Vergleich des Therapieerfolgs zweier Omeprazolpräparate und Übereinstimmung zwischen zwei Untersuchern beim Equinen Gastric Ulcer Syndrome (EGUS) (2022)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Barton, Ann Kristin (WE 17)

Trachsel, Dagmar (WE 17)

Merle, Roswitha (WE 16)

Gehlen, Heidrun (WE 17)

Quelle

Pferdeheilkunde : offizielles Organ der DVG, Fachgruppe Pferdekrankheiten = Equine medicine

Bandzählung: 38

Heftzählung: 2

Seiten: 118 – 126

ISSN: 0177-7726

Verweise

URL (Volltext): https://www.pferdeheilkunde.de/10.21836/PEM20220203

DOI: 10.21836/PEM20220203

Kontakt

Institut für Veterinär-Epidemiologie und Biometrie

Königsweg 67
14163 Berlin
+49 30 838 56034
epi@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Equine Gastric Ulcer Syndrome (EGUS) is a common problem in equine athletes. The ECEIM consensus statement and the manufacturers recommend omeprazole at a dosage of 2–4 mg/kg PO SID (buffered formulations) or 1–2 mg/kg PO SID (enteric coated granules) for the treatment of ESGD (Equine Squamous Gastric Disease) and the same dosages in combination with sucralfate (12 mg/kg PO BID) for EGGD (Equine Glandular Gastric Disease). In this study, the two formulations were compared in an equine hospital setting. A modified clinical scoring was used to include 87 horses (January 2019-December 2020) presented for recurrent colic, weight loss, exercise insufficiency or typical behavior (bruxism, groaning), in which gastroscopy was performed. Horses were classified as 0–4 for ESGD (consensus statement) and 0–3 for EGGD (modified from non-remarkable/mild/moderate/severe findings according to the Consensus statement) by the veterinarian performing the gastroscopy and led to the recommendation of therapy in 63 cases. Omeprazole therapy (buffered formulation 4 mg/kg PO SID, GastroGard™, Boehringer Ingelheim or enteric coated granules 2 mg/kg PO SID, Equizol™, CP Pharma), in case of EGGD combined with sucralfate (12 mg/kg PO BID, Sucrabest™, Combustin) was recommended in combination with improvements concerning housing, feeding and reduction of stress according to the ECEIM consensus statement. Gastroscopy was repeated about 4 weeks later in 23 horses. Standing images were randomized and scored twice by two blinded, experienced observers (ECEIM diplomats), so that 4 scorings for both time-points were available of ESGD and EGGD. The mean values of these scorings were the basis for the evaluation of treatment success. Additionally, inter- and intra-observer agreement were compared for ESGD and EGGD. Both formulations were highly effective in improving ESGD by ≥ 2 subgrades or by achieving grade 0 in 93 % and 100 % of horses treated with buffered (n = 15 GastroGard™) and encapsulated formulations (n = 8, Equizol™), respectively. EGGD was improved by ≥ 1 subgrade or achieving grade 0 in 64 % and 71 % of horses treated with bufferedand enteric coated formulations combined with sucralfate, respectively. No significant differences between the two formulations were found for either ESGD or EGGD (P > 0.999). Inter- and intra-observer-agreement were excellent for ESGD (κ = 0.832–0.975), while the inter-observer agreement for EGGD was found to be fair (κ = 0,390). In conclusion, both omeprazole formulations can be recommended for the treatment of EGUS, in particular ESGD. Differences in long-term effect and recurrence rates should be studied in future studies.